Rapidly progressive interstitial lung disease associated with dermatomyositis—Longitudinal course of anti‐MDA5 antibody titer in two cases
| Autor: | Yoshihide Asano, Tetsuo Toyama, Kentaro Awaji, Tomonori Oka, Shinichi Sato, Yuki Fukui |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pathology
medicine.medical_specialty Cyclophosphamide business.industry Interstitial lung disease Dermatology Dermatomyositis RC581-607 medicine.disease Tacrolimus Longitudinal Course Titer antimelanoma differentiation‐associated gene 5 antibody intravenous immunoglobulin RL1-803 medicine Immunology and Allergy negative conversion cyclophosphamide Immunologic diseases. Allergy business Anti mda5 antibody tacrolimus medicine.drug combined immunosuppressive therapy |
| Zdroj: | Journal of Cutaneous Immunology and Allergy, Vol 4, Iss 4, Pp 78-81 (2021) |
| ISSN: | 2574-4593 |
| Popis: | Antimelanoma differentiation‐associated gene 5 antibody (anti‐MDA5 Ab)‐positive dermatomyositis frequently develops life‐threatening rapidly progressive interstitial lung disease (RP‐ILD). The longitudinal dynamics of antibody titers reflects treatment responses, and negative conversion of anti‐MDA5 Ab leads to the prevention of RP‐ILD relapse. Case 1 finally achieved negative conversion of anti‐MDA5 Ab after 18‐month immunosuppressive therapy despite early diagnosis from skin manifestations. Case 2 showed re‐elevation of anti‐MDA5 Ab after tacrolimus discontinuation; immediate restart of tacrolimus recovered it without relapse. These cases suggest that anti‐MDA5 Ab monitoring is essential to determine therapeutic strategy in dermatomyositis patients with RP‐ILD during both initial and maintenance phases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text